+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Sunesis Pharmaceuticals Announces Presentation Of Preliminary Data From Phase 1b 2 Trial Of Vecabrutinib In Patients With Cll And Other B Cell Malignancies At Eha Annual Meeting is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Press Release Sunesis Pharmaceuticals Announces Presentation Of Preliminary Data From Phase 1b 2 Trial Of Vecabrutinib In Patients With Cll And Other B Cell Malignancies At Eha Annual Meeting | RobinsPost News & Noticias

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting


March 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals ... Annual Meeting, to be held April 3-7, 2024, in Florence, Italy. Details for the Oral and poster presentations can be found below: ... Read More

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting


Title: Brilaroxazine Efficacy and Safety in the Phase 3 RECOVER Trial in Acute Schizophrenia Poster Number: LB-008 Date: Wednesday, March 27, 2024 Time: 5:00 – 6:30 pm MT Presenter: Laxminarayan Bhat, ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus